Clinical characteristics of the 4 patients who developed clonal cytogenetic abnormalities without the morphologic features of myelodysplastic syndrome
| Patient no. . | Age at diagnosis of AA, y . | Severity of AA at diagnosis . | Previous therapies . | Response to treatment after 6 mo . | Cumulative dose of G-CSF, mg/kg . | No. of days of G-CSF therapy . | Duration of AA to MDS, mo . | Karyotype . | Survival from diagnosis of AA, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | Moderate | None | NR | 1.1 | 68 | 37 | + 8 | > 82 |
| 2 | 12 | Very severe | None | PR | 0.7 | 122 | 12 | + 8 | > 69 |
| 3 | 18 | Very severe | None | NR | 2.1 | 214 | 19 | del(13)(q14q21) | > 73 |
| 4 | 7 | Moderate | HDMP, CyA, AND | NR | 1.5 | 95 | 58 | + 8 | > 873-150 |
| Patient no. . | Age at diagnosis of AA, y . | Severity of AA at diagnosis . | Previous therapies . | Response to treatment after 6 mo . | Cumulative dose of G-CSF, mg/kg . | No. of days of G-CSF therapy . | Duration of AA to MDS, mo . | Karyotype . | Survival from diagnosis of AA, mo . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | Moderate | None | NR | 1.1 | 68 | 37 | + 8 | > 82 |
| 2 | 12 | Very severe | None | PR | 0.7 | 122 | 12 | + 8 | > 69 |
| 3 | 18 | Very severe | None | NR | 2.1 | 214 | 19 | del(13)(q14q21) | > 73 |
| 4 | 7 | Moderate | HDMP, CyA, AND | NR | 1.5 | 95 | 58 | + 8 | > 873-150 |
AA indicates aplastic anemia; G-CSF, granulocyte colony-stimulating factor; MDS, myelodysplastic syndrome; NR, no response; and PR, partial response; HDMP, high-dose methylprednisolone; CyA, cyclosporin; AND, androgen.
Patient underwent bone marrow transplantation.